• Product Name:Ibrutinib
  • Molecular Formula:C25H24N6O2
  • Purity:99%
  • Molecular Weight:440.505

Product Details:

CasNo: 936563-96-1

Molecular Formula: C25H24N6O2

Buy High Grade Ibrutinib,Hot Sale 936563-96-1 Low Price

  • Molecular Formula:C25H24N6O2
  • Molecular Weight:440.505
  • Boiling Point:715.0±60.0 °C at 760 mmHg 
  • PKA:4.09±0.30(Predicted) 
  • Flash Point:386.2±32.9 °C 
  • PSA:99.16000 
  • Density:1.3±0.1 g/cm3 
  • LogP:4.73640 

Ibrutinib(Cas 936563-96-1) Usage


Ibrutinib, marketed under the brand name Imbruvica, is a potent kinase inhibitor medication used in the treatment of various blood cancers and complications of allogeneic stem cell transplants. It belongs to the class of medications known as kinase inhibitors, and specifically targets Bruton's tyrosine kinase (BTK), an enzyme crucial for the survival and proliferation of certain cancer cells.

Ibrutinib is primarily indicated for the treatment of blood cancers, including:

Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
Mantle cell lymphoma (MCL)
Waldenstrom's Macroglobulinemia (WM)
Diffuse large B cell lymphoma (DLBCL)
Multiple myeloma (MM)
Follicular lymphoma (FL)

Regulatory Approval Ibrutinib was approved by regulatory agencies such as the FDA and the European Commission for the treatment of various blood cancers, including MCL and CLL/SLL.

936563-96-1 Relevant articles

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

Anthony R. Mato,1 Chadhi Nabhan,2 Meghan C. Thompson,1 Nicole Lamanna,3 Danielle M. Brander,4 Brian Hill,5 Christina Howlett,6,7 Alan Skarbnik,7 Bruce D. Cheson,8 Clive Zent,9 Jeffrey Pu,10 Pavel Kiselev,11 Andre Goy,7 David Claxton,10 Krista Isaac,12 Kaitlin H. Kennard,1 Colleen Timlin,1 Daniel Landsburg,1 Allison Winter,5 Sunita D. Nasta,1 Spencer H. Bachow,3 Stephen J. Schuster,1 Colleen Dorsey,1 Jakub Svoboda,1 Paul Barr,13,* and Chaitra S. Ujjani8,*

, Haematologica. 2018 May; 103(5): 874–879.

Six hundred sixteen ibrutinib-treated patients were identified. A total of 546 (88%) patients were treated with the commercial drug. Clinical trial patients were younger (mean age 58 versus 61 years, P=0.01) and had a similar time from diagnosis to treatment with ibrutinib (mean 85 versus 87 months, P=0.8).

The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study

Wyndham H. Wilson MD, PhD 1, John F. Gerecitano MD, PhD 2, Andre Goy MD 3, Sven de Vos MD, PhD 4, Vaishalee P. Kenkre MD 5, Paul M. Barr MD 6, Kristie A. Blum MD 7, Andrei R. Shustov MD * 8, Ranjana H. Advani MD 9, Jason Lih PhD * 10, Mickey Williams PhD * 10, Roland Schmitz PhD * 1, Yandan Yang PhD * 1, Stefania Pittaluga MD, PhD 1, George Wright PhD * 1, Lori A. Kunkel MD 11, Jesse McGreivy MD 11, Sriram Balasubramanian PhD 11, Mei Cheng PhD * 12, Davina Moussa * 11…Louis M. Staudt MD, PhD 13

blood, Volume 120, Issue 21, 16 November 2012, Page 686

Here, we present interim results of a phase 2 study in relapsed/refractory DLBCL of ibrutinib, a first in class inhibitor of BTK, a kinase in the BCR pathway. We tested the hypothesis that ibrutinib would be more active in ABC than GCB DLBCL due to their different addiction pathways, and we assessed the association of CD79B and MYD88 mutations with response.

936563-96-1 Upstream products

  • 814-68-6

    acryloyl chloride

  • 936563-86-9

    tert-butyl 3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate

  • 330792-69-3


  • 330792-68-2


Relevant Products